# Thomas Mandrup-Poulsen

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 175 papers | 15,003 citations | 17440 63 h-index | 18647 119 g-index |
| 181 all docs | 181 docs citations | 181 times ranked | 16348 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Celebrities in the heart, strangers in the pancreatic beta cell: Voltageâ€gated potassium channels K‹sub›v‹/sub›7.1 and K‹sub›v‹/sub›11.1 bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes. Acta Physiologica, 2022, 234, e13781. | 3.8 | 6 |
| 2 | Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in Î²-Cells. Biomedicines, 2022, 10, 814. | 3.2 | 3 |
| 3 | Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V. Scientific Reports, 2021, 11, 12253. | 3.3 | 10 |
| 4 | Divalent Metal Transporter 1 Knock-Down Modulates IL-1Î² Mediated Pancreatic Beta-Cell Pro-Apoptotic Signaling Pathways through the Autophagic Machinery. International Journal of Molecular Sciences, 2021, 22, 8013. | 4.1 | 4 |
| 5 | Proinflammatory Cytokines Perturb Mouse and Human Pancreatic Islet Circadian Rhythmicity and Induce Uncoordinated Î²-Cell Clock Gene Expression via Nitric Oxide, Lysine Deacetylases, and Immunoproteasomal Activity. International Journal of Molecular Sciences, 2021, 22, 83. | 4.1 | 6 |
| 6 | Interleukin-6 receptor blockade or TNFÎ± inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. Arthritis Research and Therapy, 2020, 22, 206. | 3.5 | 20 |
| 7 | Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipotoxicity-Induced Apoptosis in Î²-Cells. International Journal of Molecular Sciences, 2020, 21, 8016. | 4.1 | 3 |
| 8 | The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets. International Journal of Molecular Sciences, 2020, 21, 4311. | 4.1 | 5 |
| 9 | The intermediate proteasome is constitutively expressed in pancreatic beta cells and upregulated by stimulatory, low concentrations of interleukin 1ÂÎ². PLoS ONE, 2020, 15, e0222432. | 2.5 | 13 |
| 10 | The inducible Î²5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient Î²-cells and is overexpressed in type 2 diabetes pancreatic islets. American Journal of Physiology - Endocrinology and Metabolism, 2020, 318, E892-E900. | 3.5 | 7 |
| 11 | Mitophagy protects Î² cells from inflammatory damage in diabetes. JCI Insight, 2020, 5, . | 5.0 | 67 |
| 12 | Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin secretion of human pancreatic beta cells related to diabetes in thalassemia. PeerJ, 2020, 8, e9298. | 2.0 | 1 |
| 13 | Title is missing!. , 2020, 15, e0222432. | | 0 |
| 14 | Title is missing!. , 2020, 15, e0222432. | | 0 |
| 15 | Title is missing!. , 2020, 15, e0222432. | | 0 |
| 16 | Title is missing!. , 2020, 15, e0222432. | | 0 |
| 17 | Title is missing!. , 2020, 15, e0222432. | | 0 |
| 18 | Title is missing!. , 2020, 15, e0222432. | | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. Free Radical Research, 2019, 53, 694-703. | 3.3 | 5 |
| 20 | The Lysine Demethylase KDM5B Regulates Islet Function and Glucose Homeostasis. Journal of Diabetes Research, 2019, 2019, 1-15. | 2.3 | 15 |
| 21 | Targeting innate immune mediators in type 1 and type 2 diabetes. Nature Reviews Immunology, 2019, 19, 734-746. | 22.7 | 237 |
| 22 | Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 94 Is Essential for Proinsulin Handling. Diabetes, 2019, 68, 747-760. | 0.6 | 52 |
| 23 | Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Seminars in Immunopathology, 2019, 41, 413-425. | 6.1 | 28 |
| 24 | No direct effect of SGLT2 activity on glucagon secretion. Diabetologia, 2019, 62, 1011-1023. | 6.3 | 58 |
| 25 | Neuromedin U Does Not Act as a Decretin in Rats. Cell Metabolism, 2019, 29, 719-726.e5. | 16.2 | 9 |
| 26 | Metabolism and the inflammasome in health and ageing. Nature Reviews Endocrinology, 2018, 14, 72-74. | 9.6 | 9 |
| 27 | Lysine demethylase inhibition protects pancreatic Î² cells from apoptosis and improves Î²-cell function. Molecular and Cellular Endocrinology, 2018, 460, 47-56. | 3.2 | 22 |
| 28 | Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia, 2018, 61, 389-398. | 6.3 | 16 |
| 29 | Increased Plasma Ferritin Concentration and Low-Grade Inflammationâ€"A Mendelian Randomization Study. Clinical Chemistry, 2018, 64, 374-385. | 3.2 | 24 |
| 30 | MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory Î²-cell damage. PLoS ONE, 2018, 13, e0203713. | 2.5 | 17 |
| 31 | The No-Go and Nonsense-Mediated RNA Decay Pathways Are Regulated by Inflammatory Cytokines in Insulin-Producing Cells and Human Islets and Determine Î²-Cell Insulin Biosynthesis and Survival. Diabetes, 2018, 67, 2019-2037. | 0.6 | 16 |
| 32 | Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. Journal of Biological Chemistry, 2018, 293, 14224-14236. | 3.4 | 42 |
| 33 | Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. Physiological Reports, 2018, 6, e13788. | 1.7 | 8 |
| 34 | Iron Status and Gestational Diabetesâ€"A Meta-Analysis. Nutrients, 2018, 10, 621. | 4.1 | 52 |
| 35 | Glucolipotoxic conditions induce Î²-cell iron import, cytosolic ROS formation and apoptosis. Journal of Molecular Endocrinology, 2018, 61, 69-77. | 2.5 | 44 |
| 36 | Regulation of the Î²-cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. Molecular and Cellular Endocrinology, 2018, 478, 106-114. | 3.2 | 19 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The immunoproteasome is induced by cytokines and regulates apoptosis in human islets. Journal of Endocrinology, 2017, 233, 369-379. | 2.6 | 26 |
| 38 | Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study. Diabetes Care, 2017, 40, 1771-1778. | 8.6 | 51 |
| 39 | A guiding map for inflammation. Nature Immunology, 2017, 18, 826-831. | 14.5 | 506 |
| 40 | Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No. Diabetes, 2017, 66, 2937-2939. | 0.6 | 4 |
| 41 | JNK1 Deficient Insulin-Producing Cells Are Protected against Interleukin-1Î²-Induced Apoptosis Associated with Abrogated Myc Expression. Journal of Diabetes Research, 2016, 2016, 1-15. | 2.3 | 9 |
| 42 | A Systematic Comparison of Purification and Normalization Protocols for Quantitative MicroRNA Expressional Profiling in Insulin-Producing Cells. International Journal of Molecular Sciences, 2016, 17, 896. | 4.1 | 1 |
| 43 | Interleukinâ€1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. European Journal of Immunology, 2016, 46, 1030-1046. | 2.9 | 54 |
| 44 | Iron Regulation of Pancreatic Beta-Cell Functions and Oxidative Stress. Annual Review of Nutrition, 2016, 36, 241-273. | 10.1 | 73 |
| 45 | MicroRNAs as regulators of betaâ€cell function and dysfunction. Diabetes/Metabolism Research and Reviews, 2016, 32, 334-349. | 4.0 | 62 |
| 46 | Cytokines and Pancreatic Î²-Cell Apoptosis. Advances in Clinical Chemistry, 2016, 75, 99-158. | 3.7 | 85 |
| 47 | An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in Î²-Cell Protection. ACS Chemical Biology, 2016, 11, 363-374. | 3.4 | 78 |
| 48 | TRAF2 mediates JNK and STAT3 activation in response to IL-1Î² and IFNÎ³ and facilitates apoptotic death of insulin-producing Î²-cells. Molecular and Cellular Endocrinology, 2016, 420, 24-36. | 3.2 | 19 |
| 49 | A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. PLoS ONE, 2016, 11, e0154727. | 2.5 | 7 |
| 50 | Skeletal Muscle to Pancreatic Î²-Cell Cross-talk: The Effect of Humoral Mediators Liberated by Muscle Contraction and Acute Exercise on Î²-Cell Apoptosis. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E1289-E1298. | 3.6 | 39 |
| 51 | Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice. Metabolism: Clinical and Experimental, 2015, 64, 283-295. | 3.4 | 41 |
| 52 | Helsinki alert of biodiversity and health. Annals of Medicine, 2015, 47, 218-225. | 3.8 | 95 |
| 53 | Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. Diabetes, Obesity and Metabolism, 2015, 17, 703-707. | 4.4 | 90 |
| 54 | HDAC Inhibitor-Mediated Beta-Cell Protection Against Cytokine-Induced Toxicity Is STAT1 Tyr701 Phosphorylation Independent. Journal of Interferon and Cytokine Research, 2015, 35, 63-70. | 1.2 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice. PLoS ONE, 2015, 10, e0132910. | 2.5 | 9 |
| 56 | JNK1 Protects against Glucolipotoxicity-Mediated Beta-Cell Apoptosis. PLoS ONE, 2014, 9, e87067. | 2.5 | 33 |
| 57 | Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6J Mice. Journal of Biological Chemistry, 2014, 289, 16032-16045. | 3.4 | 33 |
| 58 | Altering Î²-cell number through stable alteration of miR-21 and miR-34a expression. Islets, 2014, 6, e27754. | 1.8 | 42 |
| 59 | Total and Cause-Specific Mortality by Elevated Transferrin Saturation and Hemochromatosis Genotype in Individuals With Diabetes: Two General Population Studies. Diabetes Care, 2014, 37, 444-452. | 8.6 | 10 |
| 60 | Need for Reclassification of Diabetes Secondary to Iron Overload in the ADA and WHO Classifications. Diabetes Care, 2014, 37, e137-e138. | 8.6 | 5 |
| 61 | Interleukin-1 Antagonism: A Sturdy Companion for Immune Tolerance Induction in Type 1 Diabetes?. Diabetes, 2014, 63, 1833-1835. | 0.6 | 5 |
| 62 | Inhibition of beta cell growth and function by bone morphogenetic proteins. Diabetologia, 2014, 57, 2546-2554. | 6.3 | 33 |
| 63 | Ageâ€dependent decline of Î²â€cell function in type 1 diabetes after diagnosis: a multiâ€centre longitudinal study. Diabetes, Obesity and Metabolism, 2014, 16, 262-267. | 4.4 | 79 |
| 64 | Iron: the hard player in diabetes pathophysiology. Acta Physiologica, 2014, 210, 717-732. | 3.8 | 105 |
| 65 | Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. Journal of Neuroinflammation, 2014, 11, 27. | 7.2 | 26 |
| 66 | Skeletal muscle apolipoprotein B expression reduces muscular triglyceride accumulation. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 351-357. | 1.2 | 6 |
| 67 | Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and Î²-cell protection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1055-1059. | 7.1 | 58 |
| 68 | Type 2 Diabetes Mellitus. Dermatologic Clinics, 2013, 31, 495-506. | 1.7 | 23 |
| 69 | Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology, 2013, 149, 279-285. | 3.2 | 56 |
| 70 | Serum adipokines as biomarkers of betaâ€cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes/Metabolism Research and Reviews, 2013, 29, 166-170. | 4.0 | 35 |
| 71 | Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915. | 13.7 | 301 |
| 72 | Interleukin-1 antagonists for diabetes. Expert Opinion on Investigational Drugs, 2013, 22, 965-979. | 4.1 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Total Mortality by Elevated Transferrin Saturation in Patients With Diabetes. Diabetes Care, 2013, 36, 2646-2654. | 8.6 | 13 |
| 74 | The lysine deacetylase inhibitor givinostat inhibits Î²-cell IL-1Î² induced IL-1Î² transcription and processing. Islets, 2012, 4, 417-422. | 1.8 | 12 |
| 75 | Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes. Diabetes Care, 2012, 35, 1654-1662. | 8.6 | 237 |
| 76 | Perspective: Testing failures. Nature, 2012, 485, S17-S17. | 27.8 | 3 |
| 77 | TiSH â€" a robust and sensitive global phosphoproteomics strategy employing a combination of TiO2, SIMAC, and HILIC. Journal of Proteomics, 2012, 75, 5749-5761. | 2.4 | 174 |
| 78 | Divalent Metal Transporter 1 Regulates Iron-Mediated ROS and Pancreatic Î² Cell Fate in Response to Cytokines. Cell Metabolism, 2012, 16, 449-461. | 16.2 | 133 |
| 79 | 19F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells. Archives of Biochemistry and Biophysics, 2012, 517, 138-143. | 3.0 | 16 |
| 80 | Transcriptional and translational regulation of cytokine signaling in inflammatory Î²-cell dysfunction and apoptosis. Archives of Biochemistry and Biophysics, 2012, 528, 171-184. | 3.0 | 32 |
| 81 | Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. Diabetologia, 2012, 55, 2421-2431. | 6.3 | 77 |
| 82 | Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade. Diabetes, 2012, 61, 145-154. | 0.6 | 98 |
| 83 | RNA modifications by oxidation: A novel disease mechanism?. Free Radical Biology and Medicine, 2012, 52, 1353-1361. | 2.9 | 174 |
| 84 | Interleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes. Review of Diabetic Studies, 2012, 9, 338-347. | 1.3 | 16 |
| 85 | Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus. Molecular Medicine, 2011, 17, 378-390. | 4.4 | 217 |
| 86 | The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet Î² Cells In Vivo and In Vitro. Molecular Medicine, 2011, 17, 369-377. | 4.4 | 99 |
| 87 | Direct demonstration of NCAMcis-dimerization and inhibitory effect of palmitoylation using the BRET<sup>2</sup>technique. FEBS Letters, 2011, 585, 58-64. | 2.8 | 9 |
| 88 | Apolipoprotein CIII Reduces Proinflammatory Cytokine-Induced Apoptosis in Rat Pancreatic Islets via the Akt Prosurvival Pathway. Endocrinology, 2011, 152, 3040-3048. | 2.8 | 20 |
| 89 | Cytokines and Type 1 Diabetes: A Numbers Game. Diabetes, 2011, 60, 697-699. | 0.6 | 21 |
| 90 | Elevated Transferrin Saturation and Risk of Diabetes: Three population-based studies. Diabetes Care, 2011, 34, 2256-2258. | 8.6 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. Nephron Clinical Practice, 2011, 118, c309-c314. | 2.3 | 8 |
| 92 | Role of IL-1Î² in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 314-321. | 2.3 | 284 |
| 93 | Blockade of interleukin 1 in type 1 diabetes mellitus. Nature Reviews Endocrinology, 2010, 6, 158-166. | 9.6 | 204 |
| 94 | The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. Diabetologia, 2010, 53, 10-20. | 6.3 | 252 |
| 95 | Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia, 2010, 53, 2569-2578. | 6.3 | 66 |
| 96 | Serum Proteome Pool Changes in Type 2 Diabetic Patients Treated with Anakinra. Clinical Proteomics, 2010, 6, 153-161. | 2.1 | 1 |
| 97 | IAPP boosts islet macrophage IL-1 in type 2 diabetes. Nature Immunology, 2010, 11, 881-883. | 14.5 | 33 |
| 98 | High Glucose Suppresses Human Islet Insulin Biosynthesis by Inducing miR-133a Leading to Decreased Polypyrimidine Tract Binding Protein-Expression. PLoS ONE, 2010, 5, e10843. | 2.5 | 76 |
| 99 | Proinflammatory Cytokines Activate the Intrinsic Apoptotic Pathway in Î²-Cells. Diabetes, 2009, 58, 1807-1815. | 0.6 | 195 |
| 100 | Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes. Diabetes Care, 2009, 32, 1663-1668. | 8.6 | 347 |
| 101 | Inhibition of Nuclear Factor-Î°B or Bax Prevents Endoplasmic Reticulum Stress- But Not Nitric Oxide-Mediated Apoptosis in INS-1E Cells. Endocrinology, 2009, 150, 4094-4103. | 2.8 | 31 |
| 102 | Suppressor of cytokine signalling-3 inhibits tumor necrosis factor-alpha induced apoptosis and signalling in beta cells. Molecular and Cellular Endocrinology, 2009, 311, 32-38. | 3.2 | 35 |
| 103 | IL-1 receptor antagonism andÂmuscle gene expression inÂpatients withÂtype 2 diabetes. European Cytokine Network, 2009, 20, 81-87. | 2.0 | 11 |
| 104 | G Protein-Coupled Receptor 39 Deficiency Is Associated with Pancreatic Islet Dysfunction. Endocrinology, 2009, 150, 2577-2585. | 2.8 | 82 |
| 105 | The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 240-241. | 2.8 | 37 |
| 106 | Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of Î²-Cell Function in Therapeutic Trials in Type 1 Diabetes. Diabetes Care, 2008, 31, 1966-1971. | 8.6 | 250 |
| 107 | Cytokines and Î²-Cell Biology: from Concept to Clinical Translation. Endocrine Reviews, 2008, 29, 334-350. | 20.1 | 201 |
| 108 | The Fas pathway is involved in pancreatic beta cell secretory function. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2861-2866. | 7.1 | 83 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Diabetes and Suppressors of Cytokine Signaling Proteins. Diabetes, 2007, 56, 541-548. | 0.6 | 54 |
| 110 | Interleukin-1â€"Receptor Antagonist in Type 2 Diabetes Mellitus. New England Journal of Medicine, 2007, 356, 1517-1526. | 27.0 | 1,579 |
| 111 | Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. Diabetologia, 2007, 50, 779-789. | 6.3 | 123 |
| 112 | Proliferation of sorted human and rat beta cells. Diabetologia, 2007, 51, 91-100. | 6.3 | 213 |
| 113 | Cytokine-Induced Proapoptotic Gene Expression in Insulin-Producing Cells Is Related to Rapid, Sustained, and Nonoscillatory Nuclear Factor-ÎºB Activation. Molecular Endocrinology, 2006, 20, 1867-1879. | 3.7 | 124 |
| 114 | RX871024 reduces NO production but does not protect against pancreatic Î²-cell death induced by proinflammatory cytokines. Biochemical and Biophysical Research Communications, 2006, 347, 1121-1128. | 2.1 | 12 |
| 115 | Suppressor of Cytokine Signaling-3 Inhibits Interleukin-1 Signaling by Targeting the TRAF-6/TAK1 Complex. Molecular Endocrinology, 2006, 20, 1587-1596. | 3.7 | 153 |
| 116 | Cytokines Downregulate the Sarcoendoplasmic Reticulum Pump Ca2+ ATPase 2b and Deplete Endoplasmic Reticulum Ca2+, Leading to Induction of Endoplasmic Reticulum Stress in Pancreatic Â-Cells. Diabetes, 2005, 54, 452-461. | 0.6 | 471 |
| 117 | Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia, 2005, 48, 251-260. | 6.3 | 144 |
| 118 | Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor ÎºB-mediated gene expression in insulin-producing INS-1E cells. Diabetologia, 2005, 48, 2582-2590. | 6.3 | 55 |
| 119 | An immune origin of type 2 diabetes?. Diabetologia, 2005, 48, 1038-1050. | 6.3 | 384 |
| 120 | Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia, 2005, 48, 2039-2050. | 6.3 | 130 |
| 121 | Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent?. Diabetes, 2005, 54, S114-S124. | 0.6 | 442 |
| 122 | Calcium Has a Permissive Role in Interleukin-1Î²-Induced c-Jun N-Terminal Kinase Activation in Insulin-Secreting Cells. Endocrinology, 2005, 146, 3026-3036. | 2.8 | 34 |
| 123 | Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells. Endocrinology, 2005, 146, 1718-1726. | 2.8 | 12 |
| 124 | Is Puberty an Accelerator of Type 1 Diabetes in IL6-174CC Females?. Diabetes, 2005, 54, 1245-1248. | 0.6 | 27 |
| 125 | Poor Pregnancy Outcome in Women With Type 2 Diabetes. Diabetes Care, 2005, 28, 323-328. | 8.6 | 255 |
| 126 | Glucose- and Interleukin-1Â-Induced Â-Cell Apoptosis Requires Ca2+ Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K+ Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets. Diabetes, 2004, 53, 1706-1713. | 0.6 | 149 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1?-mediated toxicity through inhibition of multiple nuclear factor-?B-regulated proapoptotic pathways. Diabetologia, 2004, 47, 1998-2011. | 6.3 | 51 |
| 128 | Beta Cell Death and Protection. Annals of the New York Academy of Sciences, 2003, 1005, 32-42. | 3.8 | 75 |
| 129 | Mutation Scan of a Type 1 Diabetes Candidate Gene. Annals of the New York Academy of Sciences, 2003, 1005, 332-339. | 3.8 | 5 |
| 130 | Inflammatory mediators and islet ?-cell failure: a link between type 1 and type 2 diabetes. Journal of Molecular Medicine, 2003, 81, 455-470. | 3.9 | 379 |
| 131 | Apoptotic signal transduction pathways in diabetes. Biochemical Pharmacology, 2003, 66, 1433-1440. | 4.4 | 126 |
| 132 | Calcium- and Proteasome-dependent Degradation of the JNK Scaffold Protein Islet-brain 1. Journal of Biological Chemistry, 2003, 278, 48720-48726. | 3.4 | 18 |
| 133 | Association of a functional 17beta-estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. Human Molecular Genetics, 2003, 12, 1101-1110. | 2.9 | 43 |
| 134 | IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. Diabetes Care, 2002, 25, 1192-1197. | 8.6 | 17 |
| 135 | Process measures and outcome research as tools for future improvement of diabetes treatment quality. Diabetes Research and Clinical Practice, 2002, 56, 207-211. | 2.8 | 7 |
| 136 | IL-1Î² induced protein changes in diabetes prone BB rat islets of Langerhans identified by proteome analysis. Diabetologia, 2002, 45, 1550-1561. | 6.3 | 65 |
| 137 | Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. Lancet, The, 2001, 358, 1405-1409. | 13.7 | 117 |
| 138 | Attitudes towards diabetes and its care: Evaluation before, immediately post-course and ?1 year after a practical, international inter-disciplinary course for diabetes teams.. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2001, 18, 39-44. | 0.2 | 3 |
| 139 | A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia, 2001, 44, 2115-2133. | 6.3 | 782 |
| 140 | Suppressor of cytokine signaling 3 (SOCS-3) protects Â-cells against interleukin-1Â- and interferon-Â-mediated toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 12191-12196. | 7.1 | 131 |
| 141 | The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. Immunogenetics, 2000, 52, 107-111. | 2.4 | 27 |
| 142 | Interferon-Î³ Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 830-836. | 3.6 | 49 |
| 143 | LINKAGE DISEQUILIBRIUM TESTING OF FOUR INTERLEUKIN-1 GENE-CLUSTER POLYMORPHISMS IN DANISH MULTIPLEX FAMILIES WITH INSULIN-DEPENDENT DIABETES MELLITUS. Cytokine, 2000, 12, 171-175. | 3.2 | 18 |
| 144 | GLUTATHIONE DEPLETION INHIBITS IL-1Î²-STIMULATED NITRIC OXIDE PRODUCTION BY REDUCING INDUCIBLE NITRIC OXIDE SYNTHASE GENE EXPRESSION. Cytokine, 2000, 12, 1391-1394. | 3.2 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Interferon-Â Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 830-836. | 3.6 | 45 |
| 146 | Absence of toxicity associated with adenoviral-mediated transfer of the Î²-galactosidase reporter gene to neonatal rat islets in vitro. Diabetes Research and Clinical Practice, 1999, 44, 157-163. | 2.8 | 9 |
| 147 | Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes, 1998, 47, 1537-1543. | 0.6 | 141 |
| 148 | Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1beta in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. Diabetes, 1998, 47, 1602-1608. | 0.6 | 44 |
| 149 | Interleukin-1Î²-induced Rat Pancreatic Islet Nitric Oxide Synthesis Requires Both the p38 and Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinases. Journal of Biological Chemistry, 1998, 273, 15294-15300. | 3.4 | 145 |
| 150 | Similarities in expression levels of proteins in IL-1Î² stimulated BB-DP islets and islets syngrafted to BB-DP rats. Experimental and Clinical Endocrinology and Diabetes, 1997, 105, 9-9. | 1.2 | 8 |
| 151 | DEXAMETHASONE PREVENTS INTERLEUKIN-1Î²-MEDIATED INHIBITION OF RAT ISLET INSULIN SECRETION WITHOUT DECREASING NITRIC OXIDE PRODUCTION. Cytokine, 1997, 9, 563-569. | 3.2 | 8 |
| 152 | Interleukin-1Î²-induced nitric oxide production from isolated rat islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. European Journal of Endocrinology, 1996, 134, 251-259. | 3.7 | 32 |
| 153 | Cytokines and the endocrine system. I. The immunoendocrine network. European Journal of Endocrinology, 1995, 133, 660-671. | 3.7 | 66 |
| 154 | Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. Critical Care Medicine, 1995, 23, 26-33. | 0.9 | 48 |
| 155 | Interleukin 1Î² induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. Cytokine, 1994, 6, 512-520. | 3.2 | 60 |
| 156 | Interleukin-1Î² (IL-1) Does Not Reduce the Diabetes Incidence in Diabetes-Prone Bb Rats. Autoimmunity, 1994, 17, 105-118. | 2.6 | 6 |
| 157 | Nicotinamide treatment in the prevention of insulinâ€dependent diabetes mellitus. Diabetes/metabolism Reviews, 1993, 9, 295-309. | 0.3 | 41 |
| 158 | Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic Î²-cell destruction in insulin-dependent diabetes mellitus. Cytokine, 1993, 5, 185-191. | 3.2 | 93 |
| 159 | Dietary Supplementation with co-3-Polyunsaturated Fatty Acids Decreases Mononuclear Cell Proliferation and Interleukin-1beta Content but not Monokine Secretion in Healthy and Insulin-Dependent Diabetic Individuals. Scandinavian Journal of Immunology, 1991, 34, 399-410. | 2.7 | 117 |
| 160 | Intra-Peritoneal Administration of Interleukin-1Î² Induces Impaired Insulin Release from the Perfused Rat Pancreas. Autoimmunity, 1990, 7, 1-12. | 2.6 | 7 |
| 161 | Monocyte Function in IDDM Patients and Healthy Individuals. Scandinavian Journal of Immunology, 1990, 32, 297-311. | 2.7 | 62 |
| 162 | Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. Diabetologia, 1990, 33, 731-736. | 6.3 | 70 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Cytokine-mediated beta-cell destructionâ€"the molecular effector mechanism causing IDDM?. Journal of Autoimmunity, 1990, 3, 121-122. | 6.5 | 5 |
| 164 | The Autoimmune Hypothesis of Insulin-Dependent Diabetes: 1965 to the Present. E&M Endocrinology and Metabolism, 1990, , 1-28. | 0.1 | 4 |
| 165 | Cytokines as Immune Effector Molecules in Autoimmune Endocrine Diseases with Special Reference to Insulin-Dependent Diabetes Mellitus. Autoimmunity, 1989, 4, 191-218. | 2.6 | 75 |
| 166 | Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat. European Journal of Endocrinology, 1989, 120, 92-98. | 3.7 | 8 |
| 167 | Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. European Journal of Endocrinology, 1988, 117, 302-306. | 3.7 | 24 |
| 168 | The bimodal effect of interleukin 1 on rat pancreatic beta-cells â€" stimulation followed by inhibition â€" depends upon dose, duration of exposure, and ambient glucose concentration. European Journal of Endocrinology, 1988, 119, 307-311. | 3.7 | 90 |
| 169 | Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia, 1987, 30, 474-480. | 6.3 | 102 |
| 170 | The HLAâ€IDDM association: Implications for etiology and pathogenesis of IDDM. Diabetes/metabolism Reviews, 1987, 3, 779-802. | 0.3 | 93 |
| 171 | Mechanisms of Pancreatic Islet Cell Destruction Dose-Dependent Cytotoxic Effect of Soluble Blood Mononuclear Cell Mediators on Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1986, 41, 250-259. | 5.7 | 77 |
| 172 | Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia, 1986, 29, 63-67. | 6.3 | 314 |
| 173 | Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. European Journal of Endocrinology, 1986, 113, 551-558. | 3.7 | 98 |
| 174 | Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients. Diabetologia, 1985, 28, 875-880. | 6.3 | 86 |
| 175 | Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1985, 40, 424-429. | 5.7 | 179 |